NCT03466294 2026-04-09
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
University of Colorado, Denver
Phase 2 Completed
Clinical Trials
113 trialsNCT02816021 2026-04-06
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01787487 2026-03-31
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT03264404 2026-01-27
Azacitidine and Pembrolizumab in Pancreatic Cancer
Columbia University
Phase 2 Completed
NCT01869114 2025-12-10
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT05065866 2025-12-04
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02512172 2025-12-03
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT04257448 2025-09-30
SEPION
GWT-TUD GmbH
Phase 1/2 Completed
NCT05471700 2025-09-23
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
Zhujiang Hospital
Phase NA Completed
NCT03019003 2025-09-16
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Massachusetts General Hospital
Phase 1 Completed
NCT02269280 2025-08-07
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05662956 2025-07-15
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
Hematology department of the 920th hospital
Phase 2 Completed
NCT02397720 2025-06-08
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00629343 2025-06-05
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Columbia University
Phase 1 Completed
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT04487106 2025-04-22
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03572530 2025-04-08
5-AZA
The University of Texas Health Science Center, Houston
Phase 1 Completed
NCT01892371 2025-04-06
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03450343 2024-10-28
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Medical University of South Carolina
Phase 1 Completed
NCT03047993 2024-05-14
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01928576 2024-05-03
NA_00084192
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03572387 2024-04-30
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT05433532 2024-04-25
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The First Affiliated Hospital of Soochow University
Phase 2 Completed
NCT03206021 2024-04-05
COZMOS
The Hospital for Sick Children
Phase 1 Completed
NCT01812252 2024-02-15
ICT-HCT
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT03390296 2023-09-05
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03542266 2023-08-22
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Weill Medical College of Cornell University
Phase 2 Completed
NCT04712942 2023-08-21
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig
Phase 2 Completed
NCT05188326 2023-06-08
Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients
Associazione Qol-one
Phase 3 Completed
NCT04146038 2023-05-24
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT02845297 2023-03-09
Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03194932 2023-02-14
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
St. Jude Children's Research Hospital
Phase 1 Completed
NCT04518345 2023-02-06
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT05048615 2023-01-25
Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Completed
NCT04022785 2022-10-31
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01700673 2022-10-18
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02553941 2022-10-06
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
University of California, Davis
Phase 1 Completed
NCT01845805 2022-10-04
Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02178072 2022-02-15
Window Trial 5-aza in HNSCC, T-tare
Yale University
Phase 1 Completed
NCT03072043 2022-01-24
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01462578 2021-11-15
RELAZA2
Technische Universität Dresden
Phase 2 Completed
NCT02497404 2021-09-22
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Weill Medical College of Cornell University
Phase 2 Completed
NCT03397173 2021-08-11
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01861002 2021-06-09
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT01617226 2021-05-05
RAvVA
University of Birmingham
Phase 2 Completed
NCT02811497 2021-04-01
METADUR
University Health Network, Toronto
Phase 2 Completed
NCT00398450 2021-03-03
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
University of California, San Diego
Phase 1 Completed
NCT00813124 2021-02-11
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01180322 2020-12-31
azacitidine
University of Ulm
Phase 2 Completed